03/23/23 1:00 AMOTC : KNBWY Norges Bank Terminates Its Observation On Kirin HoldingsKirin Holdings Company, Limited today announces that Norges Bank has terminated its observation on Kirin Holdings on March 22 2023, recognizing the completion of the Myanmar business transfer. Based on a recommendation of Norway’ s Council on Ethics* 1, Norges Bank placed Kirin Holdings under observation with the possibility of exclusion from its Government...RHEA-AIneutral
03/17/23 8:05 AMOTC : KNBWY, KYKOY clinical trialKyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis at the American Academy of Dermatology Annual Meeting 2023Kyowa Kirin Co., Ltd. today announces that data from the Phase 2 b study of rocatinlimab, an investigational product in patients with moderate-to-severe atopic dermatitis, will be presented in two posters at the upcoming American Academy of Dermatology 2023 Annual Meeting to be held March 17-22, 2023, in New...RHEA-AIneutral
03/07/23 8:00 AMOTC : KNBWY, KYKOY Kyowa Kirin Announces Acceptance for Presentation of Two Posters at the American Academy of Dermatology Annual Meeting 2023Kyowa Kirin Co., Ltd. today announced that data from the Phase 2 b study of rocatinlimab, an investigational product in patients with moderate-to-severe atopic dermatitis, will be presented at the upcoming American Academy of Dermatology 2023 Annual Meeting to be held in New Orleans from March 17-21, 2023. Author: Emma Guttman-Yassky, MD, PhD., Camilla Chong, MD,...RHEA-AIneutral
12/05/22 5:00 PMNasdaq, OTC : MEIP, KNBWY, KYKOY MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA MeetingMEI Pharma, Inc., a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd., a Japan- based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with...RHEA-AIneutral
11/03/22 9:00 AMNasdaq, OTC : MEIP, KNBWY, KYKOY MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that three abstracts highlighting data and information from the clinical...RHEA-AIneutral
08/04/22 10:00 PMOTC : KNBWY Kirin Holdings’ Long-term GHG Reduction Target Was Approved by the Science Based Targets*1 Initiative Based on Science-based Net-zero TargetsKirin Holdings Company, Limited has been approved as the first world company in the food and beverage processing sector with science-based net-zero targets validated by SBTi* 2 in July 2022. Kirin Holdings, with the aim of becoming "A global leader in CSV* 6”, have declared our goal of achieving net-zero emissions by 2020 under the Kirin Group Environmental Vision...RHEA-AIpositive
07/18/22 8:00 AMNasdaq, OTC : MEIP, KNBWY, KYKOY clinical trialMEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell MalignancyMEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced publication of data from the Phase 1 b clinical study of zandelisib, an orally...RHEA-AInegative
06/10/22 3:00 AMNasdaq, OTC : MEIP, KNBWY, KYKOY clinical trialMEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid CongressMEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that data from the zandelisib clinical development program, including the...RHEA-AIneutral
06/04/22 4:00 PMNasdaq, OTC : MEIP, KNBWY, KYKOY clinical trialMEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced data from the ongoing Phase 2 TIDAL study evaluating the intermittent dosing of...RHEA-AIneutral
05/26/22 5:00 PMNasdaq, OTC : MEIP, KNBWY, KYKOY MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that an abstract highlighting data and information from the Phase 2 TIDAL study...RHEA-AIneutral
